Rhode Island S2034 mandates insurers to cover buprenorphine without copayment or deductible.
Rhode Island S2034 amends the state's insurance laws to require all individual and group health insurance contracts, plans, or policies providing prescription coverage to cover at least one type of buprenorphine for each form of administration. The bill specifies that there shall be no copayment or deductible for this coverage, effective from January 1, 2027. However, health plans paired with a federally qualified health savings account may apply a deductible. Insurers are allowed to implement this benefit before the effective date.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.